

Attorney's Docket No. 002010-742

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re P	atent Application of	)	JUN
Mary N	И. BENDIG et al.	) Group Art Unit: 1644	TECH CENTER 2003
Applica	ation No.: 09/155,739	) Examiner: Phillip Gambel	TECH CENTER 1600/2900
Filed:	September 11, 1998	) Confirmation No.: 9068	
For:	THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN	) ) )	

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[]	No additional fee for submission of an IDS is required.
[]	The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
[]	A statement under 37 C.F.R. § 1.97(e) is also enclosed.
[X]	A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
[]	Charge \$ to Deposit Account No. 02-4800 for the fee due.
ſΧΙ	A check in the amount of \$ 180.00 is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: May 28, 2003

P.O. Box 1404

Alexandria, Virginia 22313-1404

(703) 836-6620

Jay F. William

Registration No. 48,036





Patent Attorney's Docket No. <u>002010-742</u>

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Pa	atent Application of	)	CEIVED
Mary N	M. BENDIG et al.	) Group Art Unit: 1644	UN A
Applica	ation No.: 09/155,739	) Examiner: Phillip Gambel	TECH CENTER 1600/2900
Filed:	September 11, 1998	) Confirmation No.: 9068	200/2900
For:	THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN	) ) )	

#### SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after the close of prosecution but prior to, or concurrently with, the payment of the issue fee, therefore under 37 C.F.R. § 1.97(d) a statement and the fee set forth in 37 C.F.R. § 1.17(p) are enclosed.

A fee in the amount of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

05/29/2003 SZEHDIE1 00000031 09155739

01 FC:1806

180.00 OP

Information Disclosure Statement Application No. <u>09/155,739</u> Attorney's Docket No. <u>002010-742</u> Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: May 28, 2003

Jay E Williams

Registration No. 48,036

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620



SHEET 1 OF 1

ATTORNEY'S DKT NO. 002010-742	APPLICATION NO. 09/155,739
APPLICANT	
Mary M. BENDIG et al.	
FILING DATE	GROUP
September 11, 1998	1644

# SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

		1	U.S. PATENT DOCUMENTS			_
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applica of Cited Document	nt RE	Issue/Publi Date DD-Y	cation
				JUN TECH OCL	<b>0 2</b> 2003	
				TECH CENT	ER 1600/2	<del>290(</del>
*		FO	REIGN PATENT DOCUMENTS			
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication		slatio No
	WO 94/16094	A2	PCT	07-21-1994		
			ATENT LITERATURE DOCUMENTS		* * * * * * * * * * * * * * * * * * *	-700
. <b>P.</b> N. 3		NON PA	TIENT ETTERATURE DOCUMENTS	***************************************		
<u> </u>	Includ	le name of author	r (in CAPITAL LETTERS), title of the article (whe rnal, serial, symposium, catalog, etc.), date, pag- publisher, city and/or country where published	en appropriate), title c e(s), volume-issue nu		
Examiner	Includ item (bool Olivier J.P. Léger et treatment of multiple	le name of author k, magazine, jour al. "Humanization sclerosis," Huma	r (in CAPITAL LETTERS), title of the article (who rnal, serial, symposium, catalog, etc.), date, page publisher, city and/or country where published n of a mouse antibody against human alpha-4 in an Antibodies, vol. 8(1), pp. 3-16 (1997).	en appropriate), title c e(s), volume-issue nu l. tegrin: A potential the	erapeutic for	
Examiner	Includitem (bool Olivier J.P. Léger et treatment of multiple Frank KOLBINGER e	le name of author k, magazine, jour al. "Humanizatior sclerosis," Huma et al., "Humaniza	r (in CAPITAL LETTERS), title of the article (who rnal, serial, symposium, catalog, etc.), date, pag- publisher, city and/or country where published n of a mouse antibody against human alpha-4 in	en appropriate), title c e(s), volume-issue nu l. tegrin: A potential the	erapeutic for	
Examiner	Includitem (bool Olivier J.P. Léger et treatment of multiple Frank KOLBINGER e	le name of author k, magazine, jour al. "Humanizatior sclerosis," Huma et al., "Humaniza	r (in CAPITAL LETTERS), title of the article (whernal, serial, symposium, catalog, etc.), date, page publisher, city and/or country where published in of a mouse antibody against human alpha-4 in an Antibodies, vol. 8(1), pp. 3-16 (1997). tion of a mouse anti-human IgE antibody: a pote	en appropriate), title c e(s), volume-issue nu l. tegrin: A potential the	erapeutic for	
Examiner	Includitem (bool Olivier J.P. Léger et treatment of multiple Frank KOLBINGER e	le name of author k, magazine, jour al. "Humanizatior sclerosis," Huma et al., "Humaniza	r (in CAPITAL LETTERS), title of the article (whernal, serial, symposium, catalog, etc.), date, page publisher, city and/or country where published in of a mouse antibody against human alpha-4 in an Antibodies, vol. 8(1), pp. 3-16 (1997). tion of a mouse anti-human IgE antibody: a pote	en appropriate), title c e(s), volume-issue nu l. tegrin: A potential the	erapeutic for	
Examiner	Includitem (bool Olivier J.P. Léger et treatment of multiple Frank KOLBINGER e	le name of author k, magazine, jour al. "Humanizatior sclerosis," Huma et al., "Humaniza	r (in CAPITAL LETTERS), title of the article (whernal, serial, symposium, catalog, etc.), date, page publisher, city and/or country where published in of a mouse antibody against human alpha-4 in an Antibodies, vol. 8(1), pp. 3-16 (1997). tion of a mouse anti-human IgE antibody: a pote	en appropriate), title c e(s), volume-issue nu l. tegrin: A potential the	erapeutic for	
Examiner	Includitem (bool Olivier J.P. Léger et treatment of multiple Frank KOLBINGER e	le name of author k, magazine, jour al. "Humanizatior sclerosis," Huma et al., "Humaniza	r (in CAPITAL LETTERS), title of the article (whernal, serial, symposium, catalog, etc.), date, page publisher, city and/or country where published in of a mouse antibody against human alpha-4 in an Antibodies, vol. 8(1), pp. 3-16 (1997). tion of a mouse anti-human IgE antibody: a pote	en appropriate), title c e(s), volume-issue nu l. tegrin: A potential the	erapeutic for	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.